Talecris Biotherapeutics

  Home About Talecris Therapeutic Areas Research & Development Donor to Patient Media Center Talecris Careers  
Therapeutic Areas Overview
Immune Deficiencies
Alpha1-Antitrypsin Deficiency
Antithrombin III Deficiency
Hyperimmune Globulin Therapies
Human Albumin
Hemophilia Therapy

Therapeutic Areas


Immune Deficiencies:
Immune deficiency disorders occur when one or more components of the human immune system is deficient or not functioning properly. One of those components is immune globulins, sometimes referred to as "Ig."  Because treatment of immune globulin deficiency is provided intravenously, these medicines are also called "IGIV" or "IVIG."  For decades IGIV has been used to treat a variety of immune system deficiencies and disorders.

Immune deficiency therapies

Alpha1-Antitrypsin (AAT) Deficiency
Alpha1-antitrypsin (AAT) deficiency, also known as Alpha-1, is a genetic (inherited) disorder that causes significant reduction in the naturally occurring blood protein alpha1-antitrypsin. A low level of alpha1-antitrypsin allows certain enzymes to attack healthy tissues in the body, primarily in the lungs. To replace missing or reduced levels of AAT, physicians often prescribe "augmentation" therapy with an alpha1-proteinase inhibitor.

Alpha-1 antitrypsin deficiency therapy

Antithrombin III Deficiency
The human body typically maintains a balance of blood proteins that slow or stop blood flow (in the case of injury) and facilitate blood flow (to prevent blood clots). Antithrombin III (AT III) is a blood protein that facilitates blood flow.  AT III deficiency is a rare inherited or spontaneously occurring disorder that can increase the risk of blood clots.

Antithrombin III therapy

Hemophlia
Hemophilia is a genetic disorder characterized by the deficiency or absence of one of the blood proteins responsible for clotting.  Talecris' antihemophilic factor is a concentrate containing factor VIII — one of the clotting factors (blood proteins) used for treating a specific type of hemophilia.

Hemophilia therapy

Hyperimmune Globulin Therapies
Hyperimmune globulin therapies are concentrated immunoglobulins used to treat patients whose immune systems have been compromised or challenged. To optimize protection, the greatest benefit comes from combining both active and passive immunization. Hyperimmune globulin products provide rapid passive immunity in the post-exposure period.

Immunoglobulin therapies

Human Albumin
Human albumin constitutes about 55% of all plasma proteins. It performs many functions including transport of small molecules in the blood and binding with toxins and heavy metals to prevent damage they might cause otherwise. One of albumin's major roles is maintaining colloid osmotic or oncotic pressure, which is essential to keeping fluids in the bloodstream instead of leaking out into other human tissues. Providing albumin by intravenous administration can correct low albumin levels.

More about human albumin

All of our products are made from human plasma. Products made from human plasma may contain infectious agents, such as viruses, that can cause disease. The risk that such products will transmit an infectious agent has been reduced by screening plasma donors for prior exposure to certain viruses, by testing for the presence of certain current virus infections, and by inactivating and/or removing certain viruses. Despite these measures, such products can still potentially transmit disease. There is also the possibility that unknown infectious agents may be present in such products. The physician should discuss the risks and benefits of these products with the patient, before prescribing or administering to the patient.

 

 

Print This Page
E-mail This Page
Talecris Biotherapeutics
Contact Talecris    Glossary    Site Map
General Conditions of Use    Privacy Statement    California Compliance
© 2008 Talecris Biotherapeutics